Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study

作者：Mikkael A. Sekeres, Valeria Santini, María Díez‐Campelo, Rami S. Komrokji, Pierre Fenaux, Michael R. Savona, Yazan F. Madanat, David Valcárcel-Ferreiras, Esther Natalie Olíva, Antoine Regnault, Kristin Creel, Nishan Sengupta, Souria Dougherty, Sheetal Shah, Libo Sun, Ying Wan, Shyamala Navada, Amer M. Zeidan, Uwe Platzbecker · 发表于：Leukemia & lymphoma/Leukemia and lymphoma · 年份：2024 · DOI：10.1080/10428194.2024.2426057 · 被引用次数：4 · 研究领域：Acute Myeloid Leukemia Research、Myeloproliferative Neoplasms: Diagnosis and Treatment、Chronic Myeloid Leukemia Treatments

To the Editor:One of the most common signs of myelodysplastic syndromes (MDS) is anemia, which is reported in up to 85% of patients at diagnosis [1, 2], with exhaustive fatigue as one of the most s...